[Treatment of upper-abdominal pain in chronic gastritis. Results of therapy with the motility regulating drug Bromopride].
After discussing the aetiological role of the reflux from the duodenum in causing and maintenance of chronic gastritis, the author studied the effect of bromopride, a drug regulating gastrointestinal motility, on the subjective complaints of individuals suffering from the disease. In a randomized double-blind trial, 31 subjects with upper abdominal complaints, histologically established antrum gastritis and endoscopic signs for disorders of pyloric function were treated with one capsule three times daily of bromopride or a placebo, over a period of three weeks. The positive therapeutic results in 12 of 13 patients on bromopride provide support for the clinical use of a drug regulating gastrointestinal motility in the treatment of duodeno-gastric reflux causing the discomfort of individuals with chronic gastritis. Subjects exhibiting a sensation of fullness and pressure, flatulence, pain in the epigastrium and eructations, were found to be most responsive to bromopride. No relationship between side-effects and drug treatment was observed.
D000005:Abdomen; D004341:Drug Evaluation; D005260:Female; D005756:Gastritis / Q000150:complications; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*
C013855:bromopride; D008787:Metoclopramide
Zur Behandlung von Oberbauchbeschwerden bei chronischer Gastritis. Therapie-Ergebnisse mit dem motilitätsregulierenden Präparat Bromoprid.